<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091572</url>
  </required_header>
  <id_info>
    <org_study_id>P03267</org_study_id>
    <nct_id>NCT00091572</nct_id>
    <nct_alias>NCT00101218</nct_alias>
  </id_info>
  <brief_title>Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)</brief_title>
  <official_title>Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to ascertain if the extended schedule of Temozolomide, which
      allows increased doses and potential depletion of the enzyme underlaying resistance, is a
      more effective treatment of metastatic melanoma than single agent dacarbazine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2004</start_date>
  <completion_date type="Actual">December 31, 2007</completion_date>
  <primary_completion_date type="Actual">December 31, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The final analysis was to be performed when at least 616 deaths had occurred.</time_frame>
    <description>Overall Survival was defined as the time from the date of randomization to the date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.</time_frame>
    <description>Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate in Subjects With Measurable Lesions</measure>
    <time_frame>Treatment continued until disease progression or unacceptable toxicity.</time_frame>
    <description>Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Response</measure>
    <time_frame>Treatment continued until disease progression or unacceptable toxicity.</time_frame>
    <description>Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">859</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Temodal, Temodar, SCH 52365</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>DTIC-Dome</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, stage IV, surgically incurable melanoma

          -  Age 18 years or older

          -  World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance
             status of 0 or 1

          -  Meets protocol requirements for specified laboratory values

          -  Must be able to take oral medication

          -  Must be disease free from cancer for period of 5 years (except for surgically cured
             carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin).

          -  Women of childbearing potential and men must be practicing a medically approved
             contraception.

          -  Must provide written informed-consent to participate in the study.

          -  Must have full recovery from major surgery or adjuvant treatment

          -  No clinically uncontrolled infectious disease including HIV or AIDS-related illness

        Exclusion Criteria:

          -  Ocular melanomas

          -  Brain Metastases

          -  Prior cytokine or chemotherapy for stage IV disease

          -  Pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>France</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A; EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul;47(10):1476-83. doi: 10.1016/j.ejca.2011.04.030. Epub 2011 May 18.</citation>
    <PMID>21600759</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2004</study_first_submitted>
  <study_first_submitted_qc>September 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2004</study_first_posted>
  <results_first_submitted>December 19, 2008</results_first_submitted>
  <results_first_submitted_qc>February 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2009</results_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Temozolomide</title>
          <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
        </group>
        <group group_id="P2">
          <title>Dacarbazine</title>
          <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="429">10 subjects in temozolomide group not treated.</participants>
                <participants group_id="P2" count="430">9 subjects in dacarbazine group not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="334">Progressive disease/relapse/death due to progressive disease</participants>
                <participants group_id="P2" count="348">Progressive disease/relapse/death due to progressive disease</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's Refusal unrelated to toxicity</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death not due to malignancy/toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Decision unrelated toxicity/PD</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing (still on treatment)</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity (Related AE)</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Temozolomide</title>
          <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
        </group>
        <group group_id="B2">
          <title>Dacarbazine</title>
          <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="429"/>
            <count group_id="B2" value="430"/>
            <count group_id="B3" value="859"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="537"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="356"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                    <measurement group_id="B2" value="253"/>
                    <measurement group_id="B3" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.</description>
        <time_frame>Treatment continued until disease progression or unacceptable toxicity. Patients will be followed for survival.</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine</title>
            <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause.</description>
          <population>Intent to Treat Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" lower_limit="2.23" upper_limit="2.43"/>
                    <measurement group_id="O2" value="2.17" lower_limit="2.14" upper_limit="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2663</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>Temozolomide events (progressions/deaths) = 401. Dacarbazine events (progressions/deaths) = 398.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival was defined as the time from the date of randomization to the date of death from any cause.</description>
        <time_frame>The final analysis was to be performed when at least 616 deaths had occurred.</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine</title>
            <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival was defined as the time from the date of randomization to the date of death from any cause.</description>
          <population>Intent to Treat Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.13" lower_limit="8.11" upper_limit="9.89"/>
                    <measurement group_id="O2" value="9.36" lower_limit="8.21" upper_limit="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9999</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Temozolomide events (deaths) = 320. Dacarbazine events (deaths) = 325.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate in Subjects With Measurable Lesions</title>
        <description>Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.</description>
        <time_frame>Treatment continued until disease progression or unacceptable toxicity.</time_frame>
        <population>Intent to treat population with measurable disease at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine</title>
            <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate in Subjects With Measurable Lesions</title>
          <description>Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.</description>
          <population>Intent to treat population with measurable disease at Baseline.</population>
          <units>Ratio</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="401"/>
                <count group_id="O2" value="388"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.10" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.07" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0718</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.12</ci_upper_limit>
            <estimate_desc>Temozolomide numerator (responders) = 55. Dacarbazine numerator (responders) = 37.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Response</title>
        <description>Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.</description>
        <time_frame>Treatment continued until disease progression or unacceptable toxicity.</time_frame>
        <population>All responders</population>
        <group_list>
          <group group_id="O1">
            <title>Temozolomide</title>
            <description>temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (&quot;7 days on / 7 days off&quot; continuously)</description>
          </group>
          <group group_id="O2">
            <title>Dacarbazine</title>
            <description>dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Response</title>
          <description>Duration of objective response was measured from the time the criteria were met for complete response or partial response to the first date that recurrent or progressive disease was objectively documented.</description>
          <population>All responders</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" lower_limit="4.17" upper_limit="6.18"/>
                    <measurement group_id="O2" value="8.31" lower_limit="6.08" upper_limit="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Temozolomide</title>
        </group>
        <group group_id="E2">
          <title>Dacarbazine</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA HAEMOLYTIC AUTOIMMUNE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NODAL ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>KERATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PHOTOPHOBIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>UVEITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="419"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>COLONIC FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>COLONIC OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="419"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="419"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="419"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PERFORMANCE STATUS DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HEPATIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INFECTIVE MYOSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SALPINGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SERRATIA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>AORTIC INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BLOOD CALCIUM INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MINI MENTAL STATUS EXAMINATION ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>OSTEOLYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>TUMOUR PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONUS MEDULLARIS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL SYMPTOM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGE URINARY TRACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="419"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PLEURAL FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL CAVITY DRAINAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>LYMPHADENECTOMY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MALIGNANT TUMOUR EXCISION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>MASTECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PLEURODESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>SKIN LESION EXCISION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>THORACIC CAVITY DRAINAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="394" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="374" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="91" subjects_affected="43" subjects_at_risk="419"/>
                <counts group_id="E2" events="58" subjects_affected="31" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="43" subjects_affected="22" subjects_at_risk="419"/>
                <counts group_id="E2" events="33" subjects_affected="17" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="563" subjects_affected="183" subjects_at_risk="419"/>
                <counts group_id="E2" events="267" subjects_affected="111" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="146" subjects_affected="79" subjects_at_risk="419"/>
                <counts group_id="E2" events="139" subjects_affected="71" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="85" subjects_affected="22" subjects_at_risk="419"/>
                <counts group_id="E2" events="47" subjects_affected="25" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="966" subjects_affected="286" subjects_at_risk="419"/>
                <counts group_id="E2" events="535" subjects_affected="206" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="456" subjects_affected="211" subjects_at_risk="419"/>
                <counts group_id="E2" events="208" subjects_affected="103" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1102" subjects_affected="253" subjects_at_risk="419"/>
                <counts group_id="E2" events="798" subjects_affected="240" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="18" subjects_at_risk="419"/>
                <counts group_id="E2" events="37" subjects_affected="24" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="90" subjects_affected="30" subjects_at_risk="419"/>
                <counts group_id="E2" events="136" subjects_affected="37" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="67" subjects_affected="49" subjects_at_risk="419"/>
                <counts group_id="E2" events="71" subjects_affected="54" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="380" subjects_affected="87" subjects_at_risk="419"/>
                <counts group_id="E2" events="114" subjects_affected="45" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="90" subjects_affected="16" subjects_at_risk="419"/>
                <counts group_id="E2" events="209" subjects_affected="40" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="384" subjects_affected="118" subjects_at_risk="419"/>
                <counts group_id="E2" events="157" subjects_affected="79" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="66" subjects_affected="20" subjects_at_risk="419"/>
                <counts group_id="E2" events="79" subjects_affected="23" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="88" subjects_affected="35" subjects_at_risk="419"/>
                <counts group_id="E2" events="102" subjects_affected="47" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="120" subjects_affected="35" subjects_at_risk="419"/>
                <counts group_id="E2" events="54" subjects_affected="31" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="135" subjects_affected="51" subjects_at_risk="419"/>
                <counts group_id="E2" events="77" subjects_affected="45" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="77" subjects_affected="22" subjects_at_risk="419"/>
                <counts group_id="E2" events="35" subjects_affected="17" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="206" subjects_affected="92" subjects_at_risk="419"/>
                <counts group_id="E2" events="115" subjects_affected="56" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="75" subjects_affected="28" subjects_at_risk="419"/>
                <counts group_id="E2" events="77" subjects_affected="29" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="81" subjects_affected="25" subjects_at_risk="419"/>
                <counts group_id="E2" events="49" subjects_affected="19" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="66" subjects_affected="25" subjects_at_risk="419"/>
                <counts group_id="E2" events="42" subjects_affected="17" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="193" subjects_affected="71" subjects_at_risk="419"/>
                <counts group_id="E2" events="91" subjects_affected="51" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="109" subjects_affected="45" subjects_at_risk="419"/>
                <counts group_id="E2" events="105" subjects_affected="48" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" events="156" subjects_affected="51" subjects_at_risk="419"/>
                <counts group_id="E2" events="45" subjects_affected="23" subjects_at_risk="421"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="214" subjects_affected="75" subjects_at_risk="419"/>
                <counts group_id="E2" events="67" subjects_affected="29" subjects_at_risk="421"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

